POSC320 EQ-5D Utility Estimates from the Caspian Trial of Durvalumab + Carboplatin/Cisplatin + Etoposide vs. Carboplatin/Cisplatin + Etoposide in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Resource Type
- Abstract
- Source
- In
Value in Health January 2022 25(1) Supplement:S210-S210 - Subject
- Language
- ISSN
- 1098-3015